Journal of Antimicrobial Chemotherapy (2001) 48, 667-675
© 2001 The British Society for Antimicrobial Chemotherapy
BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs
a Departments of Pathology and Laboratory Medicine, and b Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-4283, USA
The activity of BMS-284756 was studied against extracellular Legionella spp. and intracellular Legionella pneumophila, and for the treatment of guinea pigs with L. pneumophila pneumonia. The BMS-284756 MIC50 of 22 different Legionella spp. strains was 0.008 mg/L, compared with 0.016 and 0.125 mg/L for levofloxacin and azithromycin, respectively. BMS-284756 (1 mg/L) reduced the intracellular concentrations of two L. pneumophila strains grown in guinea pig alveolar macrophages by c. 1.5 log10 cfu/mL, and was more active than erythromycin, but less active than azithromycin or levofloxacin at the same drug concentrations. Efficacy studies of BMS-284756, levofloxacin and azithromycin were performed in guinea pigs with L. pneumophila pneumonia. In infected guinea pigs given BMS-284756 10 mg/kg ip, mean peak plasma levels were 1.8 mg/L at 0.5 h and 0.7 mg/L at 1 h post-dose. The elimination half-life in plasma was 0.5 h, and the AUC0–24 was 1.7 mg•h/L, about 2% of the AUC0–24 for a single 400 mg oral dose in man. Sixteen of 18 L. pneumophila-infected guinea pigs treated with BMS-284756 10 mg/kg ip once daily for 5 days survived for 7 days post-antimicrobial therapy, as did 11 of 12 guinea pigs treated with azithromycin 15 mg/kg ip once daily for 2 days. All 12 animals that were treated with levofloxacin 10 mg/kg ip once daily for 5 days survived. None of 12 control animals treated with saline survived. Animals treated with BMS-284756 had significantly higher residual lung counts of L. pneumophila at the end of therapy than did animals treated with levofloxacin or azithromycin, which may be attributable to the very low drug concentrations that were obtained. BMS-284756 was more active than erythromycin against L. pneumophila in infected macrophages, and effectively treated animals with experimental L. pneumophila pneumonia. These data support further studies of BMS-284756 for the treatment of Legionnaires' disease.
* Correspondence address. Clinical Microbiology Laboratory, 4 Gates, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA. Tel: +1-215-662-6651; Fax: +1-215-662-6655; E-mail: phe{at}mail.med.upenn.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Higa, M. Akamine, S. Haranaga, M. Tohyama, T. Shinzato, M. Tateyama, M. Koide, A. Saito, and J. Fujita In vitro activity of pazufloxacin, tosufloxacin and other quinolones against Legionella species J. Antimicrob. Chemother., December 1, 2005; 56(6): 1053 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Roig and J. Rello Legionnaires' disease: a rational approach to therapy J. Antimicrob. Chemother., May 1, 2003; 51(5): 1119 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Edelstein, W. J. Weiss, and M. A. C. Edelstein Activities of Tigecycline (GAR-936) against Legionella pneumophila In Vitro and in Guinea Pigs with L. pneumophila Pneumonia Antimicrob. Agents Chemother., February 1, 2003; 47(2): 533 - 540. [Abstract] [Full Text] [PDF]
|
|